文献速递神经肿瘤功能神经外科

清醒脑定位中电刺激阳性干扰反应的可重复性要求

Intraoperative electrostimulation for awake brain mapping: how many positive interference responses are required for reliability?
PubMed 文献 · J Neurosurg · 2019-09-20

该研究分析200例左半球肿瘤切除患者的清醒脑定位数据,评估语言任务在定位会话内及会话间的可重复性。结果显示完全干扰(3/3)在92.7%患者中具有统计学显著性,而双重干扰(2/3)仅在38.5%患者中显著;11例二次手术患者中仅26%区域满足全部三项可重复标准。

要点

  • 完全干扰(3/3)在多数患者中具有统计学显著性。
  • 双重干扰(2/3)仅部分患者显著,需谨慎解读。
  • 追加阳性试验至4/5可使双重干扰对多数患者显著。

核心结论

  • 电刺激试验的阳性可重复性呈分级模式,其显著性随基线错误率变化。
  • 2/3阳性结果需谨慎对待,是否追加试验取决于患者个体基线错误率。
  • 解读清醒脑定位数据时应考虑可重复性问题。

研究设计与样本

  • 回顾性分析200例成人左半球肿瘤切除患者的脑定位与基线测试数据。
  • 另分析11例因复发接受二次切除术患者的数据以评估随时间可重复性。
  • 采用控制命名任务的电刺激脑定位协议,并与术前及术中基线命名错误率进行统计比较。

主要发现

  • 200例患者中,单次干扰82例、双重干扰227例、完全干扰312例。
  • 完全干扰在92.7%患者中具有统计学显著性,双重干扰仅在38.5%患者中显著。
  • 进一步测试中,1/3的2/3试验变为2/4试验,仅在1/4患者中显著。
  • 双重干扰经后续2次阳性试验确认(4/5)后,对>90%患者可视为显著。
  • 11例二次手术患者中,仅26%初次手术阳性区域在二次手术中满足全部3项可重复标准。

关键数值与推荐

  • 术前基线命名错误率均值8.92%(范围0%-16.25%),经教育水平和年龄控制。
  • 术中基线错误率均值13.30%(范围0%-26.67%),与术前高度相关(r=0.74,p<10-10)。
  • 初始每个皮质区域进行3次电刺激试验;若2/3阳性则追加1或2次试验。
  • 完全干扰(3/3)在92.7%患者中显著;双重干扰(2/3)仅在38.5%患者中显著。
  • 双重干扰经4/5确认后对>90%患者显著。

临床怎么用

  • 清醒脑定位中遇到2/3阳性结果时应谨慎判读,避免过度依赖。
  • 可根据患者个体基线错误率决定是否追加电刺激试验。
  • 考虑将阳性试验追加至4/5以提高双重干扰结果的可信度。

局限性

  • 仅纳入左半球肿瘤患者,结果可能不适用于其他部位或病理。
  • 二次手术亚组样本量仅11例,可重复性结论受限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The purpose of this study was to characterize the reproducibility of language trials within and between brain mapping sessions. METHODS: Brain mapping and baseline testing data from 200 adult patients who underwent resection of left-hemisphere tumors were evaluated. Data from 11 additional patients who underwent a second resection for recurrence were analyzed separately to investigate reproducibility over time. In all cases, a specific protocol of electrostimulation brain mapping with a controlled naming task was used to detect language areas, and the results were statistically compared with preoperative and intraoperative baseline naming error rates. All patients had normal preoperative error rates, controlled for educational level and age (mean 8.92%, range 0%-16.25%). Intraoperative baseline error rates within the normal range were highly correlated with preoperative ones (r = 0.74, p < 10-10), although intraoperative rates were usually higher (mean 13.30%, range 0%-26.67%). Initially, 3 electrostimulation trials were performed in each cortical area. If 2 of 3 trials showed language interference, 1 or 2 additional trials were performed (depending on results). RESULTS: In the main group of 200 patients, there were 82 single interferences (i.e., positive results in 1 of 3 trials), 227 double interferences (2/3), and 312 full interferences (3/3). Binomial statistics revealed that full interferences were statistically significant (vs intraoperative baseline) in 92.7% of patients, while double interferences were significant only in 38.5% of patients, those with the lowest error rates. On further testing, one-third of the 2/3 trials became 2/4 trials, which was significant in only one-quarter of patients. Double interference could be considered significant for most patients (> 90%) when confirmed by 2 subsequent positive trials (4/5). In the 11 patients who were operated on twice, only 26% of areas that tested positive in the initial operation tested positive in the second and showed the same type of interference and the same current threshold (i.e., met all 3 criteria). CONCLUSIONS: Electrostimulation trials in awake brain mapping produced graded patterns of positive reproducibility levels, and their significance varied with the baseline error rates. The results suggest that caution is warranted when 2 of 3 trials are positive, although the need for additional trials depends on the individual patients' baseline error rates. Reproducibility issues should be considered in the interpretation of data from awake brain mapping.

来源:J Neurosurg,查看原文。版权归原作者所有。

引用

  1. Roux FE, Djidjeli I, Quéhan R, et al. Intraoperative electrostimulation for awake brain mapping: how many positive interference responses are required for reliability? J Neurosurg. 2019. PMID: 31597115. doi:10.3171/2019.6.JNS19925

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。